ANDAs By The Numbers: Metrics Look Good – But Review Processes Need Attention Too
• By Cole Werble
US FDA is approving generics at record pace, providing important statistics to support efforts by Commissioner Gottlieb to position the agency as part of the solution to concerns about high drug prices; new guidance for industry and FDA reviewers, however, suggests there is still a need for more rigor in preparing and assessing submissions.
The US FDA is duly proud of its recent ANDA approval metrics: 171 approvals and 37 tentative approvals in the first two months of fiscal 2018 (October and November 2017).
Commissioner Scott Gottlieb touted the higher number of approvals in a Jan. 3 statement that pointed to November’s 84 approvals and 23 tentative approvals as the high-water mark...
